NASDAQ
Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering option...
Federated Hermes Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 2.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi...
Gabelli Funds LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 96.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. Th...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 year...
American Century Companies Inc. trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 85.2% during the undefined quarter, according to the company in its most recent Form 13F filing wi...
Halozyme Therapeutics is a leader in the subcutaneous drug delivery niche, generating gobs of free cash flow. The company faces patent cliffs ahead for its core products and is actively trying to dive...
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said....
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...
Fisher Asset Management LLC decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 8.6% during the undefined quarter, according to the company in its most recent filing with th...
No price data available for this timeframe.